Emily Forbes

ORCID: 0000-0003-2372-0126
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Malaria Research and Control
  • Mosquito-borne diseases and control
  • Neurological disorders and treatments
  • vaccines and immunoinformatics approaches
  • Parkinson's Disease Mechanisms and Treatments
  • Complement system in diseases
  • Immune responses and vaccinations
  • Immune Cell Function and Interaction
  • Genetics and Neurodevelopmental Disorders
  • Epigenetics and DNA Methylation
  • Immunotherapy and Immune Responses
  • Genomics and Chromatin Dynamics
  • T-cell and B-cell Immunology
  • Tuberculosis Research and Epidemiology
  • Island Studies and Pacific Affairs
  • Autism Spectrum Disorder Research
  • HIV Research and Treatment
  • Monoclonal and Polyclonal Antibodies Research
  • Neurological and metabolic disorders
  • Chemokine receptors and signaling
  • Genomic variations and chromosomal abnormalities
  • Economic Zones and Regional Development
  • Genetics, Aging, and Longevity in Model Organisms
  • Genetic Neurodegenerative Diseases
  • Single-cell and spatial transcriptomics

University of Colorado Anschutz Medical Campus
2021-2025

University of Colorado Denver
2022-2024

Murdoch Children's Research Institute
2024

John Wiley & Sons (United States)
2024

University of Colorado Health
2021

University of Pennsylvania
2020-2021

The Royal Melbourne Hospital
2014

The University of Melbourne
2014

New York Institute of Technology
2012-2014

University of Oxford
2008-2013

Abstract Boosting bacillus Calmette-Guérin (BCG)-primed mice with a recombinant adenovirus expressing Mycobacterium tuberculosis Ag 85A by different administration routes has very effects on protection against aerosol challenge M. tuberculosis. Mice boosted intradermally make strong splenic CD4 and CD8 Th1 cytokine responses to 85A, but show no change in lung mycobacterial burden over BCG primed animals. In contrast, intranasally greatly reduced much weaker response an increased purified...

10.4049/jimmunol.181.7.4955 article EN The Journal of Immunology 2008-10-01

Abstract Identification of correlates protection for infectious diseases including malaria is a major challenge and has become one the main obstacles in developing effective vaccines. We investigated against liver-stage conferred by vaccination with adenoviral (Ad) modified vaccinia Ankara (MVA) vectors expressing pre-erythrocytic Ags. By classifying CD8+ T cells into effector, effector memory (TEM), central subsets using CD62L CD127 markers, we found striking differences cell generation....

10.4049/jimmunol.1100302 article EN The Journal of Immunology 2011-06-30

Adjuvants are substances that enhance immune responses and thus improve the efficacy of vaccination. Few adjuvants available for use in humans, one is most commonly used (alum) often induces suboptimal immunity protection against many pathogens. There an obvious need to develop new improved adjuvants. We have therefore taken approach adjuvant discovery uses silico modeling structure-based drug-design. As proof-of-principle we chose target interaction chemokines CCL22 CCL17 with their...

10.1073/pnas.0803453105 article EN Proceedings of the National Academy of Sciences 2008-07-12

Abstract We describe genetic and molecular properties of Tc3, a family transposable elements in Caenorhabditis elegans. About 15 Tc3 are present the genomes several different wild-type varieties C. elegans, but transposition excision not detected these strains. occur at high frequencies, however, strain TR679, mutant identified because its highly active Tc1 elements. In is responsible for spontaneous mutations affecting unc-22 gene. Tc3-induced unstable, revertants result from precise or...

10.1093/genetics/121.1.47 article EN Genetics 1989-01-01

In the light of recent emergence multidrug-resistant and extensively drug-resistant strains Mycobacterium tuberculosis, epidemic tuberculosis (TB) in populations coinfected with human immunodeficiency virus, failure bovis bacillus Calmette-Guerin (BCG) to protect against disease, new vaccines TB are urgently needed. Two promising vaccine candidates recombinant DeltaureC hly(+) BCG (recBCG), which has been developed replace current strain, modified vaccinia virus Ankara (MVA) expressing M....

10.1128/iai.00685-08 article EN Infection and Immunity 2008-12-09

Background Adjuvants enhance or modify an immune response that is made to antigen. An antagonist of the chemokine CCR4 receptor can display adjuvant-like properties by diminishing ability CD4+CD25+ regulatory T cells (Tregs) down-regulate responses. Methodology Here, we have used protein modelling create a plausible model with aim using virtual screening identify potential small molecule antagonists. A combination homology and molecular docking was in order investigate lead compounds...

10.1371/journal.pone.0008084 article EN cc-by PLoS ONE 2009-11-30

Abstract A central goal in vaccinology is the induction of high and sustained Ab responses. Protein-in-adjuvant formulations are commonly used to achieve such However, their clinical development can be limited by reactogenicity some most potent preclinical adjuvants cost complexity licensing new for human use. Also, few induce strong cellular immunity, which important protection against many diseases, as malaria. We compared classical aluminum hydroxide development, Abisco 100, CoVaccine HT,...

10.4049/jimmunol.1101004 article EN The Journal of Immunology 2011-08-04

There have been no specific guidelines regarding which genes should be tested in the clinical setting for Parkinson's disease (PD) or parkinsonism. We evaluated types of genetic testing offered PD as first step our gene curation.

10.1016/j.parkreldis.2021.10.001 article EN cc-by-nc-nd Parkinsonism & Related Disorders 2021-10-20

Abstract Replication-deficient adenovirus and modified vaccinia virus Ankara (MVA) vectors expressing single pre-erythrocytic or blood-stage Plasmodium falciparum Ags have entered clinical testing using a heterologous prime-boost immunization approach. In this study, we investigated the utility of same regimen when combining viral vectored vaccines 42-kDa C terminus Ag merozoite surface protein 1 circumsporozoite in yoelii mouse model. We find that vaccine coadministration leads to...

10.4049/jimmunol.1003783 article EN The Journal of Immunology 2011-08-30

Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine approaches targeting blood-stage merozoite antigens. However, increasing data suggest the berghei rodent may be able circumvent vaccine-induced anti-merozoite responses. Here we confirm a failure protect against berghei, despite successful antibody induction leading antigens using protein-in-adjuvant or viral vectored delivery. No subunit approach showed efficacy in mice following immunization...

10.1038/srep01706 article EN cc-by-nc-nd Scientific Reports 2013-04-23

Background Fine motor impairment is common in Huntington's disease (HD). Neurologic Music Therapy (NMT) the therapeutic application of music for neurorehabilitation. Measured by magnetoencephalography (MEG), modulation motor-related oscillations via NMT associated with restorative training. In HD, impact on fine function and neurophysiology have yet to be explored. Objective Conduct a proof-of-concept study determine feasibility MEG evaluation people HD. Methods Three participants HD...

10.1177/10538135251330979 article EN Neurorehabilitation 2025-05-11

Viral vectored vaccines have been shown to induce both T cell and antibody responses in animals humans. However, the induction of even higher level may be crucial achieving vaccine efficacy against difficult disease targets, especially Here we investigate oligomerization domain α-chain C4b-binding protein (C4 bp) as a candidate "molecular adjuvant" when fused malaria antigens expressed by human adenovirus serotype 5 (AdHu5) BALB/c mice. We demonstrate that i) C-terminal fusion an can enhance...

10.1371/journal.pone.0044943 article EN cc-by PLoS ONE 2012-09-12

Apical membrane Ag 1 (AMA1) is one of the leading candidate Ags for inclusion in a subunit vaccine against blood-stage malaria. However, efficacy Ab-inducing recombinant AMA1 protein vaccines phase IIa/b clinical trials remains disappointing. In this article, we describe development human adenovirus serotype 5 and modified vaccinia virus Ankara vectors encoding from Plasmodium chabaudi strain AS. These vectors, when used heterologous prime-boost regimen BALB/c mice, are capable inducing...

10.4049/jimmunol.1101106 article EN The Journal of Immunology 2012-04-14

ABSTRACT New tools are required to expedite the development of an effective vaccine against blood-stage infection with human malaria parasite Plasmodium falciparum. This work describes assessment ADRB assay in a mouse model, characterizing functional interaction between antimalarial serum antibodies and FcRs upon neutrophils. We describe reproducible, antigen-specific assay, dependent on FcR signaling, show that activity is induced equally by IgG1 IgG2a isotypes modulated blocking function....

10.1189/jlb.0513274 article EN cc-by Journal of Leukocyte Biology 2013-10-25

Human immunoglobulin G (IgG) plays an important role in mediating protective immune responses to malaria. Although human serum A (IgA) is the second most abundant class of antibody circulation, its contribution, if any, against malaria not clear.To explore mechanism(s) by which IgA may mediate a effect, we generated fully specific for C-terminal 19-kDa region Plasmodium falciparum merozoite surface protein 1 (PfMSP1 19), major target responses. This novel bound antigen with affinity...

10.1186/1472-6750-11-77 article EN cc-by BMC Biotechnology 2011-07-22

Cognitive impairment (CI) is one of the most feared and debilitating complications PD. No therapy has been shown to slow or prevent CI in PD.To determine associations between modifiable comorbidities, including cardiovascular disease risk factors, mood disorders, sleep characteristics, rate cognitive decline Parkinson's (PD).Data from Progression Markers Initiative (PPMI) cohort was queried for baseline characteristics. Linear mixed- effects models (LME) were used examine association factors...

10.1002/mdc3.13143 article EN Movement Disorders Clinical Practice 2020-12-22

ABSTRACT Background The beneficial off‐target effects of Bacille Calmette–Guérin (BCG) vaccination potentially include protection against allergy. Objective In the MIS BAIR trial, we aimed to determine whether neonatal BCG reduces atopic sensitisation and clinical food allergy in infants. Methods this randomised controlled 1272 neonates were allocated BCG‐Denmark vaccine (0.05 mL intradermal dose) or no at birth. Randomisation was stratified by recruitment site, mode delivery plurality...

10.1111/cea.14537 article EN cc-by Clinical & Experimental Allergy 2024-07-14

Typical (or classic) Rett syndrome (RTT) is an X-linked neurodevelopmental disorder characterized by a period of regression, partial or complete loss purposeful hand movements, and acquired speech, impaired gait, stereotyped movements. In over 95% typical RTT, pathogenic variant found in the methyl-CPG binding protein 2 gene (MECP2). Here, we describe young woman with clinically diagnosed RTT who lacked genetic diagnosis despite 20 years investigation multiple rounds sequencing MECP2 gene....

10.1002/ajmg.a.63725 article EN American Journal of Medical Genetics Part A 2024-05-22

Immunopathology of placental malaria is most significant in women their first pregnancy especially endemic areas, due to a lack protective immunity Plasmodium falciparum, which acquired successive pregnancies. In some studies (but not all), grand multigravidae (defined as 5 or more pregnancies, G5–7) are susceptible poor birth outcomes associated with compared earlier gravidities. By comparing peripheral cellular responses primigravidae (G1), second fourth (G2–4) and we sought identify key...

10.1371/journal.pone.0086160 article EN cc-by PLoS ONE 2014-01-22

The study was supported by funding from the NIHR Oxford Biomedical Research Centre program. Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against MalariaDraper et al.Cell Host & MicrobeJanuary 22, 2009In BriefProtecting both liver blood stages of infection is a long-sought goal malaria vaccine design. Recently, we described use replication-defective viral vectors expressing antigen merozoite surface protein-1...

10.1016/j.chom.2011.03.002 article EN cc-by Cell Host & Microbe 2011-03-01
Coming Soon ...